Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2037807

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2037807

Leukapheresis Market by Type (Filter, Membrane Separator, Centrifugal Device), Leukopak (Mobilized, Isolated PBMC), Application (Research [Cell & Gene Therapy, Transplantation], Therapeutic), Indication, End User, Region - Global Forecast to 2031

PUBLISHED:
PAGES: 411 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The leukapheresis market was estimated to be worth USD 90.6 million in 2026 and is poised to reach USD 138.7 million by 2031, growing at a CAGR of 8.9%. The leukopaks market was estimated to be worth USD 432.1 million in 2026 and is poised to reach USD 1,883.9 million by 2031, growing at a CAGR of 34.2%.

Scope of the Report
Years Considered for the Study2024-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD million)
SegmentsBy type, application, end user, region
Regions coveredNorth America, Europe, APAC, LATAM, MEA

This growth is driven by several key factors shaping the future of leukapheresis procedures, clinical decision-making, and advanced cell-collection workflows.

Leukapheresis Market - IMG1

The rising number of hematologic disorders and the increasing need for high-quality leukocyte collections to facilitate cell and gene therapy development and therapeutic interventions are the main factors that continue to drive growth. With the increasing use of CAR-T, TCR, NK cell therapies, and other immunotherapies, hospitals, blood centers, and apheresis units are rapidly upgrading their leukapheresis capabilities by acquiring advanced leukapheresis systems that feature automated controls, continuous, flow platforms, and GMP, compliant disposables, which help them to improve collection accuracy, maintain cell viability, and achieve timely clinical interventions.

On top of that, the increasing incidence of hematologic disorders, autoimmune diseases, and immune-mediated conditions is driving up the demand for high-quality leukocyte collections. Hospitals and research centers are leaning toward advanced leukapheresis modalities, such as continuous, flow apheresis systems, membrane-based separators, and automated GMP-compliant platforms, as they are more precise, efficient, and scalable for cell collection.

Also, the market expansion is being spurred by the transition toward digital apheresis workflows, which include electronic documentation, donor-monitoring systems, and integrated data platforms. This shift not only helps in procedure standardization but also enables remote monitoring and connectivity with cell therapy manufacturing records. Besides that, technological advances, including AI, assisted cell, quality assessment, predictive analytics, and cloud-based workflow management, are playing a part in the market growth. They increase the efficiency of collection, traceability, and usability, thus providing advanced leukapheresis solutions with increased practicality in diverse clinical and research settings, ranging from large hospitals to standalone apheresis centers.

"The disposables segment is projected to record the fastest growth by type during the forecast period."

Globally, the disposables segment dominated the leukapheresis market in 2025, primarily due to the increasing emphasis on standardized workflows, strict sterilization practices, and robust traceability requirements in healthcare systems. These factors collectively amplified the demand for single-use consumables. Disposables are essential in cell and gene therapy-related collections, where maintaining process uniformity, preventing contamination, and ensuring accurate documentation are critical. With the rapid global expansion of CGT manufacturing, including CAR-T, TCR-T, and stem-cell programs, the need for single-use kits, tubing sets, collection bags, filters, and closed-system consumables continues to rise steadily.

"The academic & research institutes segment accounted for the largest share of the leukopaks market."

By end user, the leukopaks market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2025, the academic & research institutes segment accounted for the largest share of the leukapheresis products market. The increasing number of industry-academic partnerships for conducting research on cell-based cancer therapies is driving the growth of this end-user segment.

"Asia Pacific is projected to witness the highest growth during the forecast period."

During the forecast period, the Asia Pacific region is expected to record the highest growth rate in the leukapheresis market. Some of the major reasons that work toward the growth of the market are the rising cases of hematologic disorders, the increasing use of cell and gene therapy, the development of apheresis infrastructure, and the growing investment in advanced therapeutic technologies by regional as well as global players. Moreover, the region benefits from increased public awareness of novel treatment modalities, healthcare access enhancement, rapid growth of specialty hospitals and blood transfusion centers, and higher involvement in CGT-related clinical trials. Altogether, these elements will stimulate the demand for leukapheresis procedures and consumables in Asia Pacific countries.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
  • By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
  • By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

  • By End User: Academic & Research Institutes (45%), Pharmaceutical & Biotechnology Companies (30%), Contract Research Organizations (25%)
  • By Designation: Apheresis Nurses & Practitioners (47%), Hematologists/Oncologists(22%), GMP Facility Heads (15%), and Others (16%)
  • By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and the Middle East & Africa (15%)

Research Coverage

The market study covers the leukapheresis market in various segments. It aims to estimate the market size and growth potential of this market by type, application, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their products and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report can assist established companies and newer or smaller firms in understanding market trends, enabling them to capture a larger market share. Firms that acquire the report can implement one or more of the five strategies outlined below.

This report provides insights into the following points:

  • Analysis of key drivers, restraints, opportunities, and challenges
  • Product Development/Innovation: Detailed insights on upcoming technologies and product launches in the leukapheresis market
  • Market Development: Comprehensive information about lucrative emerging markets
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the leukapheresis market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the leukapheresis market
Show more
Product Code: MD 6538

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS OF STUDY
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
  • 2.2 LEUKOPAKS MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 LEUKAPHERESIS MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.4 DISRUPTIVE TRENDS IN LEUKAPHERESIS MARKET
  • 2.5 HIGH-GROWTH SEGMENTS
  • 2.6 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN LEUKAPHERESIS MARKET
  • 3.2 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY END USER AND COUNTRY
  • 3.3 GEOGRAPHIC SNAPSHOT OF LEUKAPHERSIS MARKET
  • 3.4 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN LEUKOPAKS MARKET
  • 3.5 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE AND COUNTRY
  • 3.6 GEOGRAPHIC SNAPSHOT OF LEUKOPAKS MARKET

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Rising utilization of leukopaks in CAR-T cell therapy development
      • 4.2.1.2 Increasing incidence and clinical burden of leukemia
      • 4.2.1.3 Leukopaks and leukapheresis driving advances in research & development activities
      • 4.2.1.4 Leukopaks as key contributors to CAR-T cell therapy clinical trials
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Elevated costs of therapeutic leukapheresis and leukopak products
      • 4.2.2.2 Limited donor availability and stringent screening criteria for leukapheresis
      • 4.2.2.3 Shortage of skilled healthcare professionals in apheresis and cell therapy procedures
      • 4.2.2.4 Complications associated with therapeutic leukapheresis
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Increasing focus on leukapheresis in pediatric patients
      • 4.2.3.2 Rise in investments in CAR-T therapies in emerging economies
      • 4.2.3.3 Gaps in current leukapheresis technologies
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Infectious disease risks related to safety of blood transfusion in emerging economies
      • 4.2.4.2 Donor variability and inconsistent leukopak quality
  • 4.3 UNMET NEEDS & WHITE SPACES
    • 4.3.1 UNMET NEEDS IN LEUKAPHERESIS MARKET
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKETS
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
    • 4.5.1 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS IN LEUKAPHERESIS MARKET

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF SUPPLIERS
    • 5.1.4 BARGAINING POWER OF BUYERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS & FORECAST
    • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
    • 5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 MARKET ECOSYSTEM
    • 5.5.1 LEUKAPHERESIS MARKET PROVIDERS
    • 5.5.2 END USERS
    • 5.5.3 REGULATORY BODIES
  • 5.6 PRICING ANALYSIS (LEUKOPAKS MARKET)
    • 5.6.1 AVERAGE SELLING PRICE TREND FOR NON-MOBILIZED LEUKOPAKS, BY REGION, 2023-2025 (USD)
    • 5.6.2 AVERAGE SELLING PRICE TREND FOR MOBILIZED LEUKOPAKS, BY REGION, 2023-2025 (USD)
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT DATA FOR HS CODE 901890
    • 5.7.2 EXPORT DATA FOR HS CODE 901890
  • 5.8 REIMBURSEMENT SCENARIO
  • 5.9 KEY CONFERENCES & EVENTS (2026-2027)
  • 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.11 INVESTMENT & FUNDING SCENARIO
  • 5.12 CASE STUDY ANALYSIS
  • 5.13 IMPACT OF 2025 US TARIFF ON LEUKAPHERESIS MARKET
    • 5.13.1 INTRODUCTION
    • 5.13.2 KEY TARIFF RATES
    • 5.13.3 PRICE IMPACT ANALYSIS
    • 5.13.4 IMPACT ON REGIONS
    • 5.13.5 IMPACT ON END-USE SEGMENTS
      • 5.13.5.1 Leukapheresis
      • 5.13.5.2 Leukopaks

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVE IMPACT, PATENTS, AND INNOVATIONS

  • 6.1 TECHNOLOGY ANALYSIS
    • 6.1.1 KEY EMERGING TECHNOLOGIES
      • 6.1.1.1 Automated & AI-enabled apheresis systems
      • 6.1.1.2 Closed-loop & GMP-compliant processing systems
      • 6.1.1.3 Cryopreservation & cryo-processed leukopaks technologies
    • 6.1.2 COMPLEMENTARY TECHNOLOGIES
      • 6.1.2.1 Cell processing & manufacturing platforms (CGT ecosystem)
      • 6.1.2.2 Digital monitoring, data integration, and workflow software
    • 6.1.3 ADJACENT TECHNOLOGIES
      • 6.1.3.1 Regenerative medicine & stem cell technologies
  • 6.2 TECHNOLOGY/PRODUCT ROADMAP
    • 6.2.1 NEAR TERM (2025-2027)
    • 6.2.2 MID TERM (2028-2030)
    • 6.2.3 LONG TERM (2030+)
  • 6.3 PATENT ANALYSIS
    • 6.3.1 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 6.4 FUTURE APPLICATIONS
    • 6.4.1 CELL & GENE THERAPY (CAR-T, TCR, NK CELLS)
    • 6.4.2 DECENTRALIZED & POINT-OF-CARE CELL COLLECTION
    • 6.4.3 STEM CELL TRANSPLANTATION & REGENERATIVE MEDICINE
  • 6.5 IMPACT OF AI/GEN AI ON LEUKAPHERESIS MARKET
    • 6.5.1 INTRODUCTION
    • 6.5.2 MARKET POTENTIAL OF AI IN LEUKAPHERESIS
    • 6.5.3 AI USE CASES
    • 6.5.4 KEY COMPANIES IMPLEMENTING AI

7 SUSTAINABILITY & REGULATORY BEHAVIOR

  • 7.1 REGULATORY LANDSCAPE
    • 7.1.1 REGULATORY FRAMEWORK
      • 7.1.1.1 North America
      • 7.1.1.2 Europe
      • 7.1.1.3 Asia Pacific
      • 7.1.1.4 Latin America
      • 7.1.1.5 Middle East & Africa
    • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.3 INDUSTRY STANDARDS
  • 7.2 SUSTAINABILITY INITIATIVES
    • 7.2.1 RECYCLED AND ECO-FRIENDLY MATERIALS FOR LEUKAPHERESIS
    • 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
    • 7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 KEY STAKEHOLDERS & BUYING CRITERIA
    • 8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.1.2 BUYING CRITERIA
  • 8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
    • 8.2.1 DECISION-MAKING PROCESS
    • 8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES
    • 8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
    • 8.2.4 MARKET PROFITABILITY

9 LEUKAPHERESIS MARKET, BY PRODUCT TYPE

  • 9.1 INTRODUCTION
  • 9.2 DISPOSABLES
    • 9.2.1 SINGLE-USE, PROCEDURE-DRIVEN CONSUMPTION TO BOOST SEGMENT
    • 9.2.2 TUBING SETS & COLLECTION BAGS
      • 9.2.2.1 Rising leukapheresis procedure volumes driving demand for tubing sets & collection bags
    • 9.2.3 FILTERS & MEMBRANE CONSUMABLES
      • 9.2.3.1 Growing adoption of leukocyte removal filters in inflammatory disease management
    • 9.2.4 COLLECTION KITS & ACCESSORIES
      • 9.2.4.1 Increasing leukapheresis and leukopak collection activities driving demand for collection kits and accessories
  • 9.3 DEVICES
    • 9.3.1 CENTRIFUGAL DEVICES
      • 9.3.1.1 Increasing installation in hospitals to drive market
      • 9.3.1.2 Global volume analysis: Centrifugal devices market (2024-2031)
    • 9.3.2 MEMBRANE SEPARATORS
      • 9.3.2.1 Difficulty in separating large volumes of plasma to limit market

10 LEUKAPHERESIS MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 RESEARCH APPLICATIONS
    • 10.2.1 EXPANDING CELL & GENE THERAPY PIPELINE TO DRIVE THE SEGMENT
  • 10.3 THERAPEUTIC APPLICATIONS
    • 10.3.1 INCREASING ADOPTION OF LEUKAPHERESIS IN LEUKEMIA MANAGEMENT DRIVING MARKET GROWTH

11 LEUKAPHERESIS MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS
    • 11.2.1 RISING BLOOD DONATION AND TRANSFUSION NEEDS DRIVING LEUKAPHERESIS DEMAND
  • 11.3 HOSPITALS & TRANSFUSION CENTERS
    • 11.3.1 HIGH PROCEDURAL VOLUMES IN HOSPITALS TO DRIVE LEUKAPHERESIS DEMAND
  • 11.4 ACADEMIC & RESEARCH INSTITUTES
    • 11.4.1 INCREASING ACADEMIC-INDUSTRY COLLABORATIONS TO BOOST MARKET
  • 11.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 11.5.1 GROWING NUMBER OF CLINICAL TRIALS TO BOOST SEGMENT

12 LEUKOPAKS MARKET, BY TYPE

  • 12.1 INTRODUCTION
  • 12.2 MOBILIZED LEUKOPAKS
    • 12.2.1 INCREASING USE OF MOBILIZED LEUKOPAKS IN CLINICAL RESEARCH TO DRIVE MARKET
    • 12.2.2 GLOBAL VOLUME ANALYSIS: MOBILIZED LEUKOPAKS MARKET (2024-2031)
  • 12.3 NON-MOBILIZED LEUKOPAKS
    • 12.3.1 ADOPTION OF NON-MOBILIZED LEUKOPAKS DRIVEN BY LOWER COST AND CELL YIELD
    • 12.3.2 GLOBAL VOLUME ANALYSIS: NON-MOBILIZED LEUKOPAKS MARKET (2024-2031)
  • 12.4 DISEASED LEUKOPAKS
    • 12.4.1 INCREASING DEMAND FOR DISEASE-STATE LEUKOPAKS IN ADVANCED THERAPEUTIC RESEARCH DRIVING MARKET GROWTH"
    • 12.4.2 GLOBAL VOLUME ANALYSIS: DISEASED LEUKOPAKS MARKET (2024-2031)
  • 12.5 ISOLATED PBMCS
    • 12.5.1 INCREASING RESEARCH FOCUS ON CELL-BASED THERAPIES TO FUEL MARKET
    • 12.5.2 GLOBAL VOLUME ANALYSIS: ISOLATED PBMCS MARKET (2024-2031)

13 LEUKOPAKS MARKET, BY INDICATION

  • 13.1 INTRODUCTION
  • 13.2 ACUTE LYMPHOCYTIC LEUKEMIA
    • 13.2.1 INCREASING INCIDENCE OF ACUTE LYMPHOCYTIC LEUKEMIA SUPPORTING MARKET GROWTH
  • 13.3 MULTIPLE MYELOMA
    • 13.3.1 RISING MULTIPLE MYELOMA CASES DRIVING MARKET EXPANSION
  • 13.4 NON-HODGKIN'S LYMPHOMA
    • 13.4.1 DEVELOPMENT OF NOVEL THERAPIES TO BOOST MARKET
  • 13.5 CHRONIC LYMPHOCYTIC LEUKEMIA
    • 13.5.1 GROWING PREVALENCE OF CHRONIC LYMPHOCYTIC LEUKEMIA DRIVING SEGMENT EXPANSION
  • 13.6 PANCREATIC CANCER
    • 13.6.1 DEVELOPMENT OF NEW DIAGNOSTIC TECHNIQUES TO DRIVE SEGMENT
  • 13.7 HEPATOCELLULAR CARCINOMA
    • 13.7.1 INCREASING INCIDENCE OF VIRAL HEPATITIS TO FUEL SEGMENT
  • 13.8 OTHER INDICATIONS

14 LEUKOPAKS MARKET, BY END USER

  • 14.1 INTRODUCTION
  • 14.2 ACADEMIC & RESEARCH INSTITUTES
    • 14.2.1 INCREASING INDUSTRY-ACADEMIC COLLABORATIONS DRIVING MARKET GROWTH
  • 14.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 14.3.1 RISING DEMAND FOR TARGETED CELL-BASED DRUG DEVELOPMENT DRIVING LEUKOPAK ADOPTION
  • 14.4 CONTRACT RESEARCH ORGANIZATIONS
    • 14.4.1 INCREASING CRO-LED CLINICAL ACTIVITIES DRIVING DEMAND FOR LEUKAPHERESIS-DERIVED MATERIALS

15 LEUKAPHERESIS MARKET, BY REGION

  • 15.1 INTRODUCTION
  • 15.2 NORTH AMERICA
    • 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 15.2.2 NORTH AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE (2024-2031)
    • 15.2.3 US
      • 15.2.3.1 Strong Presence of Biopharmaceutical Leaders and Expanding Cell Therapy Ecosystem Driving Market Growth
    • 15.2.4 CANADA
      • 15.2.4.1 Increasing Leukemia Incidence and Advancements in CAR-T Therapies Supporting Market Growth in Canada
  • 15.3 EUROPE
    • 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 15.3.2 EUROPE VOLUME ANALYSIS: LEUKOPAKS TYPE (2024-2031)
    • 15.3.3 GERMANY
      • 15.3.3.1 Rising Healthcare Expenditure, Expanding Academic-Clinical Cell Therapy Ecosystem to drive market growth
    • 15.3.4 UK
      • 15.3.4.1 Expanding Apheresis Capacity and CAR-T Therapies Adoption to support market growth
    • 15.3.1 FRANCE
      • 15.3.1.1 Centralized CAR-T Delivery System and Strong Public Reimbursement to propel market growth
    • 15.3.2 ITALY
      • 15.3.2.1 Rising elderly patient pool and high cancer incidence to drive market growth
    • 15.3.3 SPAIN
      • 15.3.3.1 Rising Hematologic Cancer Burden to support market growth
    • 15.3.4 BELGIUM
      • 15.3.4.1 Strong Clinical Research Ecosystem and Structured Reimbursement Framework to boost the market
    • 15.3.5 NETHERLANDS
      • 15.3.5.1 Strong healthcare infrastructure and aging population to drive market
    • 15.3.6 POLAND
      • 15.3.6.1 Rise in cancer incidence to boost the market
    • 15.3.7 SWITZERLAND
      • 15.3.7.1 Early adoption of cell therapies to drive market demand
    • 15.3.8 REST OF EUROPE
  • 15.4 ASIA PACIFIC
    • 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 15.4.2 ASIA PACIFIC VOLUME ANALYSIS: LEUKOPAKS TYPE (2024-2031)
    • 15.4.3 CHINA
      • 15.4.3.1 Increasing hematologic cancer burden, CAR-T expansion, and biotech investments driving leukapheresis growth in China
    • 15.4.4 JAPAN
      • 15.4.4.1 Moderate-to-high healthcare expenditure supporting leukapheresis market growth
    • 15.4.5 INDIA
      • 15.4.5.1 Rising government investment in healthcare to drive market growth
    • 15.4.6 AUSTRALIA
      • 15.4.6.1 Clinical integration of CAR-T therapies in hospitals as core growth driver for leukapheresis in Australia
    • 15.4.7 SOUTH KOREA
      • 15.4.7.1 Integration of digital and automated cell processing technologies driving growth in the leukapheresis market
    • 15.4.8 NEW ZEALAND
      • 15.4.8.1 Strengthening therapeutic apheresis infrastructure as a core growth driver for the New Zealand leukapheresis market
    • 15.4.9 THAILAND
      • 15.4.9.1 Rising oncology demand for cell-based therapies driving leukapheresis market growth
    • 15.4.10 REST OF ASIA PACIFIC
  • 15.5 LATIN AMERICA
    • 15.5.1 LATIN AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE (2024-2031)
    • 15.5.2 BRAZIL
      • 15.5.2.1 Role of blood donation, transplant activity, and cell therapy expansion in driving the leukapheresis and leukopak market
    • 15.5.3 MEXICO
      • 15.5.3.1 Emerging CAR-T therapy and cost-driven leukemia care market in Mexico
    • 15.5.4 REST OF LATIN AMERICA
  • 15.6 MIDDLE EAST & AFRICA
    • 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 15.6.2 MIDDLE EAST & AFRICA VOLUME ANALYSIS: LEUKOPAKS TYPE (2024-2031)
    • 15.6.3 GCC COUNTRIES
      • 15.6.3.1 Kingdom of Saudi Arabia (KSA)
        • 15.6.3.1.1 Transforming clinical research in Saudi Arabia through healthcare innovation initiatives
      • 15.6.3.2 United Arab Emirates (UAE)
        • 15.6.3.2.1 Emergence as a Regional Hub for Advanced Precision Medicine
      • 15.6.3.3 Other GCC countries
    • 15.6.4 REST OF MIDDLE EAST & AFRICA

16 COMPETITIVE LANDSCAPE

  • 16.1 INTRODUCTION
  • 16.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2022-2026
    • 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN LEUKAPHERESIS MARKET
  • 16.3 REVENUE ANALYSIS, 2023-2025
    • 16.3.1 LEUKAPHERESIS MARKET: REVENUE ANALYSIS
    • 16.3.2 LEUKOPAKS MARKET: REVENUE ANALYSIS
  • 16.4 MARKET SHARE ANALYSIS, 2025
    • 16.4.1 LEUKAPHERESIS MARKET: SHARE ANALYSIS
    • 16.4.2 LEUKOPAKS MARKET: SHARE ANALYSIS
  • 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 16.5.1 LEUKOPAKS MARKET
      • 16.5.1.1 Stars
      • 16.5.1.2 Emerging leaders
      • 16.5.1.3 Pervasive players
      • 16.5.1.4 Participants
      • 16.5.1.5 Company footprint: Key players, 2025
        • 16.5.1.5.1 Company footprint
        • 16.5.1.5.2 By Region footprint
        • 16.5.1.5.3 By product type footprint
  • 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 16.6.1 LEUKOPAKS MARKET
      • 16.6.1.1 Progressive companies
      • 16.6.1.2 Responsive companies
      • 16.6.1.3 Dynamic companies
      • 16.6.1.4 Starting blocks
      • 16.6.1.5 Competitive benchmarking: Startups/SMEs, 2025
        • 16.6.1.5.1 Detailed list of key startups/SMEs
        • 16.6.1.5.2 Competitive benchmarking of key startups/SMEs
  • 16.7 COMPANY VALUATION AND FINANCIAL METRICS
    • 16.7.1 FINANCIAL METRICS: LEUKAPHERESIS MARKET
    • 16.7.2 COMPANY VALUATION : LEUKAPHERESIS MARKET
    • 16.7.3 FINANCIAL METRICS: LEUKOPAKS MARKET
    • 16.7.4 COMPANY VALUATION: LEUKOPAKS MARKET
  • 16.8 LEUKOPAKS BRAND/PRODUCT COMPARISON
  • 16.9 LEUKAPHEREIS BRAND/PRODUCT COMPARISON
  • 16.10 COMPETITIVE SCENARIO
    • 16.10.1 LEUKAPHERESIS MARKET
      • 16.10.1.1 Product launches & approvals
      • 16.10.1.2 Deals
      • 16.10.1.3 Expansions
    • 16.10.2 LEUKOPAKS MARKET
      • 16.10.2.1 Product launches & approvals
      • 16.10.2.2 Deals
      • 16.10.2.3 Expansions

17 COMPANY PROFILES

  • 17.1 LEUKAPHERESIS PRODUCTS MARKET: KEY PLAYERS
    • 17.1.1 TERUMO CORPORATION
      • 17.1.1.1 Business overview
      • 17.1.1.2 Products offered
      • 17.1.1.3 Recent developments
        • 17.1.1.3.1 Product launches & approvals
        • 17.1.1.3.2 Deals
        • 17.1.1.3.3 Expansions
      • 17.1.1.4 MnM view
        • 17.1.1.4.1 Right to win
        • 17.1.1.4.2 Strategic choices
        • 17.1.1.4.3 Weaknesses & competitive threats
    • 17.1.2 FRESENIUS SE & CO. KGAA
      • 17.1.2.1 Business overview
      • 17.1.2.2 Products offered
      • 17.1.2.3 Recent developments
        • 17.1.2.3.1 Product launches & approvals
        • 17.1.2.3.2 Deals
        • 17.1.2.3.3 Other developments
      • 17.1.2.4 MnM view
        • 17.1.2.4.1 Right to win
        • 17.1.2.4.2 Strategic choices
        • 17.1.2.4.3 Weaknesses & competitive threats
    • 17.1.3 HAEMONETICS CORPORATION
      • 17.1.3.1 Business overview
      • 17.1.3.2 Products offered
      • 17.1.3.3 Recent developments
        • 17.1.3.3.1 Product launches & approvals
        • 17.1.3.3.2 Deals
      • 17.1.3.4 MnM view
        • 17.1.3.4.1 Right to win
        • 17.1.3.4.2 Strategic choices
        • 17.1.3.4.3 Weaknesses & competitive threats
    • 17.1.4 NIKKISO CO., LTD.
      • 17.1.4.1 Business overview
      • 17.1.4.2 Products offered
      • 17.1.4.3 Recent developments
        • 17.1.4.3.1 Other developments
      • 17.1.4.4 MnM view
        • 17.1.4.4.1 Right to win
        • 17.1.4.4.2 Strategic choices
        • 17.1.4.4.3 Weaknesses & competitive threats
    • 17.1.5 SUMITOMO BAKELITE CO., LTD.
      • 17.1.5.1 Business overview
      • 17.1.5.2 Products offered
      • 17.1.5.3 MnM view
        • 17.1.5.3.1 Right to win
        • 17.1.5.3.2 Strategic choices
        • 17.1.5.3.3 Weaknesses & competitive threats
    • 17.1.6 DANAHER CORPORATION
      • 17.1.6.1 Business overview
      • 17.1.6.2 Products offered
    • 17.1.7 OTSUKA HOLDINGS CO., LTD.
      • 17.1.7.1 Business overview
      • 17.1.7.2 Products offered
    • 17.1.8 ASAHI KASEI MEDICAL CO., LTD.
      • 17.1.8.1 Business overview
      • 17.1.8.2 Products offered
      • 17.1.8.3 Recent developments
        • 17.1.8.3.1 Other developments
    • 17.1.9 MACOPHARMA SA
      • 17.1.9.1 Business overview
      • 17.1.9.2 Products offered
    • 17.1.10 MEDICA SPA
      • 17.1.10.1 Business overview
      • 17.1.10.2 Products offered
  • 17.2 LEUKAPHERESIS PRODUCTS MARKET: OTHER PLAYERS
    • 17.2.1 POLYMED
    • 17.2.2 PURIBLOOD MEDICAL
    • 17.2.3 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.
    • 17.2.4 SAFETRAN BIOMEDICAL INC.
    • 17.2.5 MITRA INDUSTRIES PRIVATE LIMITED
  • 17.3 LEUKOPAKS MARKET: KEY PLAYERS
    • 17.3.1 LONZA
      • 17.3.1.1 Business overview
      • 17.3.1.2 Products offered
      • 17.3.1.3 Recent developments
        • 17.3.1.3.1 Deals
      • 17.3.1.4 MnM view
        • 17.3.1.4.1 Right to win
        • 17.3.1.4.2 Strategic choices
        • 17.3.1.4.3 Weaknesses and competitive threats
    • 17.3.2 GRIFOLS
      • 17.3.2.1 Business overview
      • 17.3.2.2 Products offered
    • 17.3.3 CHARLES RIVER LABORATORIES
      • 17.3.3.1 Business overview
      • 17.3.3.2 Products offered
      • 17.3.3.3 Recent developments
        • 17.3.3.3.1 Product launches & approvals
        • 17.3.3.3.2 Deals
        • 17.3.3.3.3 Expansions
    • 17.3.4 CELLEX CELL PROFESSIONALS
      • 17.3.4.1 Business overview
      • 17.3.4.2 Products offered
      • 17.3.4.3 Recent developments
        • 17.3.4.3.1 Deals
        • 17.3.4.3.2 Expansions
    • 17.3.5 STEMCELL TECHNOLOGIES
      • 17.3.5.1 Business overview
      • 17.3.5.2 Products offered
    • 17.3.6 BIOIVT
      • 17.3.6.1 Business overview
      • 17.3.6.2 Products offered
      • 17.3.6.3 Recent developments
        • 17.3.6.3.1 Product launches & approvals
        • 17.3.6.3.2 Deals
        • 17.3.6.3.3 Expansions
    • 17.3.7 DISCOVERY LIFE SCIENCES
      • 17.3.7.1 Business overview
      • 17.3.7.2 Products offered
      • 17.3.7.3 Recent developments
        • 17.3.7.3.1 Product launches & approvals
        • 17.3.7.3.2 Deals
        • 17.3.7.3.3 Expansions
    • 17.3.8 MILTENYI BIOTEC
      • 17.3.8.1 Business overview
      • 17.3.8.2 Products offered
    • 17.3.9 STEMVIVO INC.
      • 17.3.9.1 Business overview
      • 17.3.9.2 Products offered
    • 17.3.10 CGT GLOBAL
      • 17.3.10.1 Business overview
      • 17.3.10.2 Products offered
      • 17.3.10.3 Recent developments
        • 17.3.10.3.1 Product launches & approvals
    • 17.3.11 SANGUINE BIOSCIENCES
      • 17.3.11.1 Business overview
      • 17.3.11.2 Products offered
      • 17.3.11.3 Recent developments
        • 17.3.11.3.1 Product launches & approvals
  • 17.4 LEUKOPAKS MARKET: OTHER PLAYERS
    • 17.4.1 BIOMEX GMBH
    • 17.4.2 ACCEGEN
    • 17.4.3 EXCELLOS
    • 17.4.4 FIRST CHOICE BIO INC.
    • 17.4.5 ORGANA BIO
    • 17.4.6 HUMAN CELLS BIO

18 RESEARCH METHODOLOGY

  • 18.1 RESEARCH DATA
    • 18.1.1 SECONDARY DATA
      • 18.1.1.1 Key data from secondary sources
  • 18.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS MARKET
  • 18.3 MARKET GROWTH RATE PROJECTIONS
  • 18.4 DATA TRIANGULATION
  • 18.5 RESEARCH ASSUMPTIONS
    • 18.5.1 GROWTH RATE ASSUMPTIONS
  • 18.6 RISK ASSESSMENT
  • 18.7 LIMITATIONS
    • 18.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 18.7.2 SCOPE-RELATED LIMITATIONS
  • 18.8 RESEARCH LIMITATIONS
  • 18.9 RISK ANALYSIS

19 APPENDIX

  • 19.1 DISCUSSION GUIDE
  • 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 19.3 CUSTOMIZATION OPTIONS
    • 19.3.1 COMPANY INFORMATION
    • 19.3.2 GEOGRAPHIC ANALYSIS
    • 19.3.3 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
    • 19.3.4 COUNTRY-LEVEL VOLUME ANALYSIS
    • 19.3.5 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
  • 19.4 RELATED REPORTS
  • 19.5 AUTHOR DETAILS
Show more
Product Code: MD 6538

List of Tables

  • TABLE 1 LEUKAPHERESIS MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • TABLE 3 COST OF LEUKOPAKS, BY TYPE
  • TABLE 4 DONOR SELECTION CRITERIA
  • TABLE 5 FREQUENCY OF BLOOD DONATION FROM HEALTHY DONORS
  • TABLE 6 LEUKAPHERESIS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 7 GDP CHANGE, BY KEY COUNTRY, 2021-2030 (USD BILLION)
  • TABLE 8 LIST OF KEY LEUKAPHERESIS DEVICES + DISPOSABLES MANUFACTURERS
  • TABLE 9 LIST OF KEY LEUKOPAKS MANUFACTURERS
  • TABLE 10 LIST OF KEY END USERS
  • TABLE 11 LIST OF KEY REGULATORY BODIES
  • TABLE 12 AVERAGE SELLING PRICE OF NON-MOBILIZED LEUKOPAKS, 2025 (USD)
  • TABLE 13 AVERAGE SELLING PRICE OF MOBILIZED LEUKOPAKS, 2025 (USD)
  • TABLE 14 AVERAGE SELLING PRICE OF DISEASED LEUKOPAKS, 2025 (USD)
  • TABLE 15 AVERAGE SELLING PRICE OF ISOLATED PBMCS, 2025 (USD)
  • TABLE 16 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • TABLE 17 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • TABLE 18 LEUKAPHERESIS MARKET: MAJOR CONFERENCES & EVENTS IN 2026-2027
  • TABLE 19 CASE STUDY 1: RAPID CYTOREDUCTION IN PEDIATRIC ACUTE LEUKEMIA USING LEUKAPHERESIS
  • TABLE 20 CASE STUDY 2: GLOBAL CELL THERAPY TRIAL ENABLED BY LEUKAPHERESIS INTEGRATION
  • TABLE 21 CASE STUDY 3: THERAPEUTIC LEUKAPHERESIS IN SEVERE PNEUMONIA WITH HYPERLEUKOCYTOSIS
  • TABLE 22 US-ADJUSTED RECIPROCAL TARIFF RATES, 2024
  • TABLE 23 KEY PRODUCT-RELATED TARIFF EFFECTIVE
  • TABLE 24 NORTH AMERICA: IMPACT OF US TARIFFS
  • TABLE 25 ASIA PACIFIC: IMPACT OF US TARIFFS
  • TABLE 26 EUROPE: IMPACT OF US TARIFFS
  • TABLE 27 LATIN AMERICA: IMPACT OF US TARIFFS
  • TABLE 28 LEUKAPHERESIS MARKET: KEY PATENTS, 2023-2025
  • TABLE 29 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 30 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 31 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 32 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 33 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LEUKOPAKS
  • TABLE 35 KEY BUYING CRITERIA FOR LEUKOPAKS, BY TYPE
  • TABLE 36 LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 37 DISPOSABLES: LEUKAPHERESIS MARKET, BY PRODUCT TYPE 2024-2031 (USD MILLION)
  • TABLE 38 LEUKAPHERESIS DISPOSABLE PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 39 TUBING SETS & COLLECTION BAGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 40 COMMERCIALLY AVAILABLE FILTERS & MEMBRANE CONSUMABLES
  • TABLE 41 FILTERS & MEMBRANE CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 42 COMMERCIALLY AVAILABLE COLLECTION KITS & ACCESSORIES
  • TABLE 43 COLLECTION KITS & ACCESSORIES MARKET, BY TYPE,2024-2031 (USD MILLION)
  • TABLE 44 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 45 CENTRIFUGAL DEVICES AVAILABLE
  • TABLE 46 CENTRIFUGAL DEVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 47 CENTRIFUGAL DEVICES VOLUME MARKET, 2024-2031 (UNITS SOLD)
  • TABLE 48 MEMBRANE SEPARATORS AVAILABLE
  • TABLE 49 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 50 LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 51 COMPANIES DEVELOPING FDA-APPROVED CAR-T CELL THERAPIES
  • TABLE 52 LEUKAPHERESIS MARKET IN RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 53 LEUKAPHERESIS MARKET IN THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 54 LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 55 LEUKAPHERESIS MARKET FOR BLOOD COMPONENT PROVIDERS & BLOOD CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 56 LEUKAPHERESIS MARKET FOR HOSPITALS & TRANSFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 57 LEUKAPHERESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 58 CAR-T CELL THERAPY UNDER CLINICAL TRIALS
  • TABLE 59 LEUKAPHERESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 60 LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 61 LEUKOPAKS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 62 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 63 MOBILIZED LEUKOPAKS MARKET VOLUME, BY REGION, 2024-2031 (NO. OF BAGS)
  • TABLE 64 NUMBER OF CELLS IN NON-MOBILIZED LEUKOPAKS
  • TABLE 65 COMPARATIVE ANALYSIS OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS
  • TABLE 66 COMPOSITION OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS
  • TABLE 67 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 68 NON-MOBILIZED LEUKOPAKS MARKET VOLUME, BY REGION, 2024-2031 (NO. OF BAGS)
  • TABLE 69 DISEASED CELL LEUKOPAKS AND THEIR ROLE IN CELL THERAPY
  • TABLE 70 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 71 DISEASED LEUKOPAKS MARKET VOLUME, BY REGION, 2024-2031 (NO. OF BAGS)
  • TABLE 72 IMMUNE CELL TYPES AND TARGETED DISEASES
  • TABLE 73 ISOLATED PBMCS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 74 ISOLATED PBMCS MARKET VOLUME, BY REGION, 2024-2031 (NO. OF BAGS)
  • TABLE 75 LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 76 LEUKOPAKS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 77 LEUKOPAKS MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 78 LEUKOPAKS MARKET FOR NON-HODGKIN'S LYMPHOMA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 79 LEUKOPAKS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 80 LEUKOPAKS MARKET FOR PANCREATIC CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 81 LEUKOPAKS MARKET FOR HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 82 LEUKOPAKS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 83 LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 84 LEUKOPAKS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 85 LEUKOPAKS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 86 LEUKOPAKS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 LEUKAPHERESIS PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 88 LEUKOPAKS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 89 MAJOR LEUKAPHERESIS MARKET PLAYERS IN NORTH AMERICA
  • TABLE 90 NORTH AMERICA: LEUKAPHERESIS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 91 NORTH AMERICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 92 NORTH AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 93 NORTH AMERICA: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 94 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 95 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 96 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 97 US: KEY MACROINDICATORS
  • TABLE 98 US: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 99 US: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 100 US: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 101 US: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 102 US: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 103 US: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 104 CANADA: KEY MACROINDICATORS
  • TABLE 105 CANADA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 106 CANADA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 107 CANADA: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 108 CANADA: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 109 CANADA: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 110 CANADA: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 111 EUROPE: LEUKOPAKS MARKET, BY LEUKOPAK TYPE, 2024-2031 (MILLION UNIT BAGS)
  • TABLE 112 EUROPE: LEUKAPHERESIS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 113 EUROPE: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 114 EUROPE: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 115 EUROPE: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 116 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 117 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 118 EUROPE: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 119 GERMANY: KEY MACROINDICATORS
  • TABLE 120 GERMANY: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 121 GERMANY: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 122 GERMANY: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 123 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 124 GERMANY: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 125 GERMANY: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 126 UK: KEY MACROINDICATORS
  • TABLE 127 UK: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 128 UK: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 129 UK: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 130 UK: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 131 UK: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 132 UK: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 133 FRANCE: KEY MACROINDICATORS
  • TABLE 134 SPAIN: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 135 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 136 SPAIN: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 137 SPAIN: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 138 ITALY: KEY MACROINDICATORS
  • TABLE 139 ITALY: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 140 ITALY: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 141 ITALY: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 142 ITALY: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 143 ITALY: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 144 ITALY: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 145 SPAIN: KEY MACROINDICATORS
  • TABLE 146 NETHERLANDS: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 147 NETHERLANDS: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 148 NETHERLANDS: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 149 NETHERLANDS: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 150 NETHERLANDS: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 151 NETHERLANDS: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 152 POLAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 153 POLAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 154 POLAND: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 155 POLAND: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 156 POLAND: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 157 POLAND: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 158 SWITZERLAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 159 SWITZERLAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 160 SWITZERLAND: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 161 SWITZERLAND: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 162 SWITZERLAND: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 163 SWITZERLAND: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 164 REST OF EUROPE: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 165 REST OF EUROPE: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 166 REST OF EUROPE: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 167 REST OF EUROPE: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 168 REST OF EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 169 REST OF EUROPE: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 170 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 171 ASIA PACIFIC: LEUKOPAK PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 172 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 173 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 174 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: LEUKOPAKS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 176 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 178 ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: LEUKOPAKS MARKET, BY LEUKOPAK TYPE, 2024-2031 (MILLION UNIT BAGS)
  • TABLE 180 CHINA: KEY MACROINDICATORS
  • TABLE 181 CHINA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 182 CHINA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 183 CHINA: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 184 CHINA: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 185 CHINA: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 186 CHINA: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 187 JAPAN: KEY MACROINDICATORS
  • TABLE 188 JAPAN: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 189 JAPAN: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 190 JAPAN: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 191 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 192 JAPAN: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 193 JAPAN: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 194 INDIA: KEY MACROINDICATORS
  • TABLE 195 INDIA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 196 INDIA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 197 INDIA: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 198 INDIA: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 199 INDIA: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 200 INDIA: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 201 AUSTRALIA: KEY MACROINDICATORS
  • TABLE 202 AUSTRALIA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 203 AUSTRALIA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 204 AUSTRALIA: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 205 AUSTRALIA: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 206 AUSTRALIA: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 207 AUSTRALIA: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 208 SOUTH KOREA: KEY MACROINDICATORS
  • TABLE 209 SOUTH KOREA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 210 SOUTH KOREA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 211 SOUTH KOREA: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 212 SOUTH KOREA: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 213 SOUTH KOREA: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 214 SOUTH KOREA: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 215 NEW ZEALAND: KEY MACROINDICATORS
  • TABLE 216 NEW ZEALAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 217 NEW ZEALAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 218 NEW ZEALAND: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 219 NEW ZEALAND: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 220 NEW ZEALAND: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 221 NEW ZEALAND: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 222 THAILAND: KEY MACROINDICATORS
  • TABLE 223 THAILAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 224 THAILAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 225 THAILAND: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 226 THAILAND: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 227 THAILAND: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 228 THAILAND: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 229 ROAPAC: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 230 ROAPAC: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 231 ROAPAC: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 232 ROAPAC: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 233 ROAPAC: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 234 ROAPAC: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 235 LATIN AMERICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 236 LATIN AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 237 LATIN AMERICA: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 238 LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 239 LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 240 LATIN AMERICA: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 241 BRAZIL: KEY MACROINDICATORS
  • TABLE 242 BRAZIL: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 243 BRAZIL: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 244 BRAZIL: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 245 BRAZIL: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 246 BRAZIL: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 247 BRAZIL: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 248 MEXICO: KEY MACROINDICATORS
  • TABLE 249 MEXICO: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 250 MEXICO: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 251 MEXICO: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 252 MEXICO: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 253 MEXICO: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 254 MEXICO: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 255 REST OF LATIN AMERICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 256 REST OF LATIN AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 257 REST OF LATIN AMERICA: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 258 REST OF LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 259 REST OF LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 260 REST OF LATIN AMERICA: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 261 MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 262 MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 263 MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 264 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 265 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 266 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 267 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY LEUKOPAK TYPE, 2024-2031 (MILLION UNIT BAGS)
  • TABLE 268 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
  • TABLE 269 KINGDOM OF SAUDI ARABIA (KSA): LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 270 KINGDOM OF SAUDI ARABIA (KSA): LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 271 KINGDOM OF SAUDI ARABIA (KSA): LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 272 KINGDOM OF SAUDI ARABIA (KSA): LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 273 KINGDOM OF SAUDI ARABIA (KSA): LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 274 KINGDOM OF SAUDI ARABIA (KSA): LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 275 UNITED ARAB EMIRATES (UAE): KEY MACROINDICATORS
  • TABLE 276 UNITED ARAB EMIRATES (UAE): LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 277 UNITED ARAB EMIRATES (UAE): LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 278 UNITED ARAB EMIRATES (UAE): LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 279 UNITED ARAB EMIRATES (UAE): LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 280 UNITED ARAB EMIRATES (UAE): LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 281 UNITED ARAB EMIRATES (UAE): LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 282 OTHER GCC COUNTRIES: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 283 OTHER GCC COUNTRIES: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 284 OTHER GCC COUNTRIES: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 285 OTHER GCC COUNTRIES: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 286 OTHER GCC COUNTRIES: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 287 OTHER GCC COUNTRIES: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 288 REST OF MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 289 REST OF MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 290 REST OF MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 291 REST OF MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 292 REST OF MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 293 REST OF MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 294 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN LEUKAPHERESIS MARKET, JANUARY 2023-MARCH 2026
  • TABLE 295 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN LEUKOPAKS MARKET, JANUARY 2023-MARCH 2026
  • TABLE 296 LEUKAPHERESIS MARKET: DEGREE OF COMPETITION
  • TABLE 297 LEUKOPAKS MARKET: DEGREE OF COMPETITION
  • TABLE 298 LEUKOPAKS MARKET: REGION FOOTPRINT
  • TABLE 299 LEUKOPAKS MARKET: BY PRODUCT TYPE FOOTPRINT
  • TABLE 300 LEUKOPAKS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 301 LEUKOPAKS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS
  • TABLE 302 LEUKAPHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 303 LEUKAPHERESIS MARKET: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 304 LEUKAPHERESIS MARKET: EXPANSIONS, JANUARY 2023-MARCH 2026
  • TABLE 305 LEUKOPAKS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 306 LEUKOPAKS MARKET: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 307 LEUKOPAKS MARKET: EXPANSIONS, JANUARY 2023-MARCH 2026
  • TABLE 308 TERUMO CORPORATION: COMPANY OVERVIEW
  • TABLE 309 TERUMO CORPORATION: PRODUCTS OFFERED
  • TABLE 310 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 311 TERUMO CORPORATION: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 312 TERUMO CORPORATION: EXPANSIONS, JANUARY 2023-MARCH 2026
  • TABLE 313 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW
  • TABLE 314 FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED
  • TABLE 315 FRESENIUS SE & CO. KGAA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 316 FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 317 FRESENIUS SE & CO. KGAA: OTHER DEVELOPMENTS, JANUARY 2023-MARCH 2026
  • TABLE 318 HAEMONETICS CORPORATION: COMPANY OVERVIEW
  • TABLE 319 HAEMONETICS CORPORATION: PRODUCTS OFFERED
  • TABLE 320 HAEMONETICS CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 321 HAEMONETICS CORPORATION: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 322 NIKKISO CO., LTD.: COMPANY OVERVIEW
  • TABLE 323 NIKKISO CO., LTD.: PRODUCTS OFFERED
  • TABLE 324 NIKKISO CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023-MARCH 2026
  • TABLE 325 SUMITOMO BAKELITE CO., LTD.: COMPANY OVERVIEW
  • TABLE 326 SUMITOMO BAKELITE CO., LTD.: PRODUCTS OFFERED
  • TABLE 327 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 328 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 329 OTSUKA HOLDINGS CO., LTD.: COMPANY OVERVIEW
  • TABLE 330 OTSUKA HOLDINGS CO., LTD: PRODUCTS OFFERED
  • TABLE 331 ASAHI KASEI MEDICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 332 ASAHI KASEI MEDICAL CO., LTD.: PRODUCTS OFFERED
  • TABLE 333 ASAHI KASEI MEDICAL CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023-MARCH 2026
  • TABLE 334 MACOPHARMA SA: COMPANY OVERVIEW
  • TABLE 335 MACOPHARMA SA: PRODUCTS OFFERED
  • TABLE 336 MEDICA SPA: COMPANY OVERVIEW
  • TABLE 337 MEDICA SPA: PRODUCTS OFFERED
  • TABLE 338 POLYMED: COMPANY OVERVIEW
  • TABLE 339 PURIBLOOD MEDICAL: COMPANY OVERVIEW
  • TABLE 340 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 341 SAFETRAN BIOMEDICAL INC.: COMPANY OVERVIEW
  • TABLE 342 MITRA INDUSTRIES PRIVATE LIMITED: COMPANY OVERVIEW
  • TABLE 343 LONZA: COMPANY OVERVIEW
  • TABLE 344 LONZA: PRODUCTS OFFERED
  • TABLE 345 LONZA: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 346 GRIFOLS: COMPANY OVERVIEW
  • TABLE 347 GRIFOLS: PRODUCTS OFFERED
  • TABLE 348 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY OVERVIEW
  • TABLE 349 CHARLES RIVER LABORATORIES: PRODUCTS OFFERED
  • TABLE 350 CHARLES RIVER LABORATORIES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 351 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 352 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2023-MARCH 2026
  • TABLE 353 CELLEX CELL PROFESSIONALS: COMPANY OVERVIEW
  • TABLE 354 CELLEX CELL PROFESSIONALS: PRODUCTS OFFERED
  • TABLE 355 CELLEX CELL PROFESSIONALS: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 356 CELLEX CELLS PROFESSIONALS: EXPANSIONS, JANUARY 2023-MARCH 2026
  • TABLE 357 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 358 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED
  • TABLE 359 BIOIVT: COMPANY OVERVIEW
  • TABLE 360 BIOIVT: PRODUCTS OFFERED
  • TABLE 361 BIOIVT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 362 BIOIVT: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 363 BIOIVT: EXPANSIONS, JANUARY 2023-MARCH 2026
  • TABLE 364 DISCOVERY LIFE SCIENCES: COMPANY OVERVIEW
  • TABLE 365 DISCOVERY LIFE SCIENCES: PRODUCTS OFFERED
  • TABLE 366 DISCOVERY LIFE SCIENCES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 367 DISCOVERY LIFE SCIENCES: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 368 DISCOVERY LIFE SCIENCES: EXPANSIONS, JANUARY 2023-MARCH 2026
  • TABLE 369 MILTENYI BIOTEC: COMPANY OVERVIEW
  • TABLE 370 MILTENYI BIOTEC: PRODUCTS OFFERED
  • TABLE 371 STEMVIVO INC.: COMPANY OVERVIEW
  • TABLE 372 STEMVIVO INC.: PRODUCTS OFFERED
  • TABLE 373 CGT GLOBAL: COMPANY OVERVIEW
  • TABLE 374 CGT GLOBAL: PRODUCTS OFFERED
  • TABLE 375 CGT GLOBAL: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 376 SANGUINE BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 377 SANGUINE BIOSCIENCES: PRODUCTS OFFERED
  • TABLE 378 SANGUINE BIOSCIENCES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 379 BIOMEX GMBH: COMPANY OVERVIEW
  • TABLE 380 ACCEGEN: COMPANY OVERVIEW
  • TABLE 381 EXCELLOS: COMPANY OVERVIEW
  • TABLE 382 FIRST CHOICE BIO INC.: COMPANY OVERVIEW
  • TABLE 383 ORGANA BIO: COMPANY OVERVIEW
  • TABLE 384 HUMAN CELLS BIO: COMPANY OVERVIEW
  • TABLE 385 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON LEUKAPHERESIS MARKET
  • TABLE 386 RISK ASSESSMENT: LEUKAPHERESIS MARKET

List of Figures

  • FIGURE 1 LEUKAPHERESIS MARKET: SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 LEUKAPHERESIS MARKET: YEARS CONSIDERED
  • FIGURE 3 MARKET SCENARIO
  • FIGURE 4 LEUKAPHERESIS MARKET, 2026-2031
  • FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LEUKOPAKS MARKET, 2024-2026
  • FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LEUKAPHERESIS MARKET, 2024-2026
  • FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF LEUKAPHERESIS MARKET
  • FIGURE 8 HIGH-GROWTH SEGMENTS IN LEUKOPAKS MARKET, 2026-2031
  • FIGURE 9 HIGH-GROWTH SEGMENTS IN LEUKAPHERESIS MARKET, 2026-2031
  • FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN LEUKAPHERESIS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
  • FIGURE 11 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN LEUKOPAKS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
  • FIGURE 12 GROWING INCIDENCE OF CANCER TO DRIVE MARKET
  • FIGURE 13 BLOOD COMPONENT PROVIDERS AND BLOOD CENTERS SEGMENT AND JAPAN ACCOUNTED FOR LARGEST MARKET SHARES IN 2025
  • FIGURE 14 CHINA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 15 GROWING PREVALENCE OF LEUKEMIA AND ADOPTION OF CAR T-CELL THERAPY TO DRIVE MARKET
  • FIGURE 16 MOBILIZED LEUKOPAKS SEGMENT AND CHINA ACCOUNTED FOR LARGEST MARKET SHARES IN 2025
  • FIGURE 17 CHINA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 18 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 19 ESTIMATED NUMBER OF NEW LEUKEMIA CASES, BY REGION (2020 VS. 2040)
  • FIGURE 20 ESTIMATED NUMBER OF LEUKEMIA DEATHS, BY REGION (2020 VS. 2040)
  • FIGURE 21 LEUKAPHERESIS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 22 LEUKAPHERESIS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 23 LEUKAPHERESIS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 24 LEUKOPAKS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 LEUKAPHERESIS MARKET ECOSYSTEM
  • FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS IN LEUKAPHERESIS MARKET
  • FIGURE 27 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES IN LEUKOPAKS MARKET
  • FIGURE 28 INVESTMENT & FUNDING SCENARIO FOR LEUKAPHERESIS MARKET PLAYERS
  • FIGURE 29 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR LEUKAPHERESIS PATENTS (JANUARY 2015-MARCH 2026)
  • FIGURE 30 LEUKAPHERESIS MARKET: AI USE CASES
  • FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LEUKOPAKS
  • FIGURE 32 KEY BUYING CRITERIA FOR LEUKOPAKS, BY TYPE
  • FIGURE 33 NORTH AMERICA: LEUKAPHERESIS MARKET SNAPSHOT
  • FIGURE 34 NORTH AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024-2031 (NO. OF BAGS)
  • FIGURE 35 EUROPE VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024-2031 (NO. OF BAGS)
  • FIGURE 36 ASIA PACIFIC: LEUKAPHERESIS MARKET SNAPSHOT
  • FIGURE 37 ASIA PACIFIC VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024-2031 (NO. OF BAGS)
  • FIGURE 38 LATIN AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024-2031 (NO. OF BAGS)
  • FIGURE 39 MIDDLE EAST & AFRICA VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024-2031 (NO. OF BAGS)
  • FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN LEUKAPHERESIS MARKET, 2023-2025
  • FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN LEUKOPAKS MARKET, 2023-2025
  • FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LEUKAPHERESIS MARKET, 2025
  • FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LEUKOPAKS MARKET, 2025
  • FIGURE 44 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 45 LEUKOPAKS MARKET: COMPANY FOOTPRINT
  • FIGURE 46 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 47 EV/EBITDA OF KEY VENDORS FOR LEUKAPHERESIS
  • FIGURE 48 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FOR LEUKAPHERESIS
  • FIGURE 49 EV/EBITDA OF KEY VENDORS FOR LEUKOPAKS
  • FIGURE 50 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FOR LEUKOPAKS
  • FIGURE 51 LEUKOPAKS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 52 LEUKAPHERESIS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 53 TERUMO CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 54 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2025)
  • FIGURE 55 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 56 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 57 SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 58 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 59 OTSUKA HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 60 LONZA: COMPANY SNAPSHOT (2025)
  • FIGURE 61 GRIFOLS: COMPANY SNAPSHOT (2025)
  • FIGURE 62 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 63 LEUKAPHERESIS MARKET: RESEARCH DESIGN
  • FIGURE 64 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET)
  • FIGURE 65 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKAPHERESIS MARKET)
  • FIGURE 66 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER AND REGION (LEUKAPHERESIS MARKET)
  • FIGURE 67 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET)
  • FIGURE 68 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER AND REGION (LEUKOPAKS MARKET)
  • FIGURE 69 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 70 REVENUE SHARE ANALYSIS ILLUSTRATION: TERUMO CORPORATION (2025)
  • FIGURE 71 DEMAND-SIDE APPROACH: LEUKAPHERESIS MARKET (2025)
  • FIGURE 72 LEUKAPHERESIS MARKET: CAGR PROJECTIONS (2026-2031)
  • FIGURE 73 TOP-DOWN APPROACH
  • FIGURE 74 DATA TRIANGULATION METHODOLOGY
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!